In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis (ZTS – Research Report). The ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...

Investment analysts at William Blair reduced their Q1 2025 EPS estimates for shares of Zoetis in a note issued to investors ...

Zoetis has been granted a conditional license from the USDA for its avian flu vaccine. Since February 2022, more than 150 ...

The New Jersey-based drugmaker secured a conditional license to protect chickens with its H5N2 subtype vaccine.